Q-omics provides the consensus-scored HSPA1L profile across patient tissues and cancer cell-line models. HSPA1L expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HSPA1L is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, HSPA1L RNA expression shows 19,584 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where HSPA1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPA1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPA1L survival associations across molecular data types. HSPA1L RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPA1L RNA expression–survival associations across cancer types. High HSPA1L expression shows unfavorable associations in COAD and LUAD, but favorable associations in KIRC, HNSC, UVM and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HSPA1L RNA expression.
This table summarizes HSPA1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for HSPA1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPA1L shows lower tumor expression in THCA, BLCA, KICH, UCEC and LUAD and higher tumor expression in LIHC. The THCA box plot shows higher HSPA1L RNA expression in normal versus tumor tissue (log2 FC = −1.132, t-test p < 0.001).
This table shows molecular features associated with HSPA1L in patient tissues and cancer cell lines. In patient samples, HSPA1L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HSPA1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
